CSH guidelines for the diagnosis and treatment of drug-induced liver injury
Tóm tắt
Từ khóa
Tài liệu tham khảo
Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425
Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55–68
Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guide: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966
Hillman L, Gottfried M, Whitsett M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol. 2016;111(7):958–965
Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–1934
Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–2076
Miguel A, Azevedo LF, Araújo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2012;21(11):1139–1154
Li L, Jiang W, Wang JY. Clinical analysis of 275 cases of acute drug-induced liver disease. Front Med China. 2007;1(1):58–61
Hoofnagle JH, Serrano J, Knoben JE, et al. LiverTox: a website on drug-induced liver injury. Hepatology. 2013;57(3):873–874
Yimin M. HepaTox: The professional networking platform for promoting clinical and translational research of drug-induced liver injury in China. Chin Hepatol 2014;(8):575–576 (article in Chinese)
Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145–155
Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115–122
Lai RT, Wang H, Gui HL, et al. Clinical and pathological features in 138 cases of drug-induced liver injury. Chin J Hepatol 2012;20(3):185–189 (article in Chinese)
Hao KY, Yu YC, He CL, et al. Analysis on the diagnosis, clinical features and prognosis of 140 cases with drug-induced liver injury based on the RUCAM scales. Chin J Hepatol 2014;22(12):82–85 (article in Chinese)
Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018–1023
Bjornsson E, Jerlstad P, Bergqvist A, et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40(9):1095–1101
Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes. Cell Biochem Biophys. 2012;64(2):77–83
Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol. 2011;7(7):875–890
Hoofnagle JH, Navarro VJ. Drug-induced liver injury: Icelandic lessons. Gastroenterology. 2013;144(7):1335–1336
Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49(6):2001–2009
Elinav E, Pinsker G, Safadi R, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol. 2007;47(4):514–520
Azizi F, Amouzegar A. Management of hyperthyroidism during pregnancy and lactation. Eur J Endocrinol. 2011;164:871–876
Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13(2):369–376
Saadi T, Waterman M, Yassin H, et al. Metformin-induced mixed hepatocellular and cholestatic hepatic injury: case report and literature review. Int J Gen Med. 2013;6:703–706
Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22(1):1–13
Pais R, Rusu E, Ratziu V. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin Liver Dis. 2014;18(1):165–178
Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44(6):1581–1588
Sharma SK1, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166(7):916–919
Pukenyte E, Lescure FX, Rey D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis 2007;11(1):78–84
Mitchell JR, Long MW, Thorgeirsson UP, et al. Acetylation rates and monthly liverfunction tests during one year of isoniazid preventive therapy. Chest. 1975;68(2):181–190
Shayiq RM, Roberts DW, Rothstein K, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology. 1999;29(2):451–463
Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994;271(13):992–998
Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology. 2011;53(4):1377–1387
Khandelwal N, James LP, Sanders C, et al. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011;53(2):567–576
Guengerich FP. Cytochrome P450 Activation of Toxins and Hepatotoxicity. In Kaplowitz N, DeLeve LD. Drug Induced Liver Disease, 3rd ed. New York: Elsevier; 2013. 15–33
Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44(1):116–126
Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology. 2010;52(2):748–761
Wei CY, Lee MTM, Chen YT. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum Mol Genet. 2012;21(R1):R58–R65
Alfirevic A, Gonzalez-Galarza F, Bell C, et al. In silico analysis of HLA associations with drug-induced liver injury use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med. 2012;4(6):51
Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenom J. 2008;8(3):186–195
Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nature. 2010;42(8):711–714
Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012;44(1):34–87
Goncalves RL, Rothschild DE, Quinlan CL, et al. Sources of superoxide/H2O2 during mitochondrial proline oxidation. Redox Biol. 2014;2:901–909
Choumar A, Tarhuni A, Letteron P, et al. Lipopolysaccharide-induced mitochondrial DNA depletion. Antioxid Redox Signal. 2011;15:2837–2854
Kim JS, He L, Qian T, et al. Role of the mitochondrial permeability transition in apoptotic and necrotic death after ischemia/reperfusion injury to hepatocytes. Curr Mol Med. 2003;3(6):527–535
Nakagawa H, Maeda S, Hikiba Y, et al. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology. 2008;135:1311–1321
Jaeschke H, McGill MR, Williams CD, et al. Current issues with acetaminophen hepatotoxicity—a clinically relevant model to test the efficacy of natural products. Life Sci. 2011;88(17–18):737–745
Martin-Murphy BV, Holt MP, Ju C. The role of damage associated molecular pattern molecules in acetaminophen induced liver injury in mice. Toxicol Lett 2010;192(3):387–394
Janssens S, Pulendran B, Lambrecht BN. Emerging functions of the unfolded protein response in immunity. Nat Immunol. 2014;15(10):910–919
Dara L, Ji C, Neil Kaplowitz N. The contribution of endoplasmic reticulum stress to liver diseases. Hepatology. 2011;55(5):1752–1763
Fredriksson L, Wink S, Herpers B, et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity. Toxicol Sci. 2014;140(1):144–159
Lai R, Xiang X, Mo R, et al. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. J Hepatol. 2015;63(1):148–155
Masson MJ, Collins LA, Pohl LR. The role of cytokines in the mechanism of adverse drug reactions. Handb Exp Pharmacol. 2010;196:195–231
Vandenabeele P, Galluzzi L, Vanden Berghe T, et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11(10):700–714
Ke PY, Chen SS. Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases. Viruses 2012;4(10):2251–2290
Henkel A, Green RM. The unfolded protein response in fatty liver disease. Semin Liver Dis. 2013;33(4):321–329
Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146(4):914–928
Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin Drug Saf. 2014;13(1):67–81
Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev. 2012;44(1):107–115
Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–2259
Eisenberg-Lerner A, Kimchi A. PKD is a kinase of Vsp34 that mediates ROS-induced autophagy downstream of DAPk. Cell Death Differ 2012;19:788–797
Ding WX, Manley S, Ni HM. The emerging role of autophagy in alcoholic liver disease. Exp Biol Med. 2011;236:546–556
Roth RA, Ganey PE. Role of inflammation in drug-induced liver injury. In: Kaplowitz N, Deleve LD, editors. Drug-Induced Liver Disease. 3rd ed. San Diego: Academic Press; 2013. 157–173
Wu MH, Zang P, Huang X. Toll-like receptors in innate immunity and infectious diseases. Front Med China. 2010;4(4):385–393
Hansen JD, Vojtech LN, Laing KJ. Sensing disease and danger: a survey of vertebrate PRRs and their origins. Dev Comp Immunol. 2011;35(9):886–897
Mehendale HM. Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol Pathol. 2005;33(1):41–51
Kleiner DE. Histopathological Evaluation of Drug-Induced Liver Disease. In Kaplowttz N, DeLeve LD, ed. Drug-induced Liver Disease, 3rd ed. New York, Academic Press; 2013. 241–261
Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62(6):481–492
Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22(4):335–353
Tang W. Drug metabolite profiling and elucidation of drug induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2007;3(3):407–420
Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–144
Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129(2):512–521
Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):730–742
Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108
Borraz, Y, Fernandez MC, Garcia-Muhoz B, et al. Would it be desirable to modify the cut-off point for definition of chronicity in drug-induced liver injury (DILI)? In 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010. A270
Robles-Diaz M, Lucena MI, Kaplowitz N, et al; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-Based Translation Consortium. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014;147(1):109–118
Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis. 2012;13(1):33–39
Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2014;4(4):332–346
Kootte AM, Siegel AM, Koorenhof M. Generalised peliosis hepatis mimicking metastases after long-term use of oral contraceptives. Neth J Med. 2015;73(1):41–43
Yu CY, Chang LC, Chen LW, et al. Peliosis hepatis complicated by portal hypertension following renal transplantation. World J Gastroenterol. 2014;20(9):2420–2425
Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367–1384
Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011;(3)34:243–252
Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48(5):1680–1689
Fannin RD, Russo M, O’Connell TM, et al. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology. 2010;51(1):227–236
Su YW, Chen X, Jiang ZZ, et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS One. 2012;7(5):e37395
Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 2012;56(5):1946–1957
Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013;58(2):777–787
Watkins PB. Biomarkers for drug-induced liver injury. In: Kaplowitz N, Deleve LD, editors. Drug-Induced Liver Disease. 3rd ed. San Diego: Academic Press; 2013. 275–286.
Kenna JG. Current concepts in drug-induced bile salt export pump (BSEP) interference. Curr Protoc Toxicol 2014;61:23.7.1–23.7.15
Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol. 2014;4(4):286–292
Lin G, Wang JY, Li N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011;54(4):666–673
Vuppalanchi R, iangpunsakul S, Chalsani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States. Am J Gastroenterol 2007;102(3):558–562
Loras C, Gisber JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59(10):1340–1346
Makar GA, Weiner MG, Kimmel SE, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf. 2008;17(1):43–51
Aithal GP, Watkins PB, Andrade RJ. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–815
Danan G, Benichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–1330
http://livertox.nlm.nih.gov/rucam.html . Accessed 28 Mar 2017
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14–46
Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. Hepatology. 1997;26(3):664–669
Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123–130
García-Cortés M, Lucena MI, Pachkoria K, et al. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27(9):780–789
Hepatobiliary Diseases Cooperation Group of CSG. Recommendations for the diagnosis and treatment of acute drug-induced liver injury (draft). Chin J Dig 2007;27(11):765–767 (articles in Chinese).
Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel–Uclaf causality assessment method. Hepatology. 2010;51(6):2117–2126
Research Group of Liver Failure and Artificial Liver; Society of Infectious Disease (SID); Chinese Medical Association (CMA); Research Group of Severe Liver Disease and Artificial Liver; Chinese Society of Hepatology (CSH); CMA. Guidelines for diagnosis and treatment of liver failure (2012 edition). Chin J Hepatol 2013;21(3):178–179 (articles in Chinese).
Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the study of liver diseases position paper on acute liver failure 2011. Hepatology. 2012;55(3):965–967
http://livertox.nlm.nih.gov/Severity.html . Accessed 28 Mar 2017
Palmore TN, Shah NL, Loomba R, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol. 2009;7(10):1130–1137
Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54(3):931–939
Miao Q, Bian Z, Tang R, et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin Rev Allergy Immunol. 2015;48(2–3):226–235
Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–2048
Wu S, Xia Y, Lv X, et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a largecohort of Chinese patients. J Gastroenterol Hepatol. 2015;30(3):540–545
Ford R, Schwartz L, Dancey J, US Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER), et al. Guidance for industry: drug-induced liver injury—premarketing clinical evaluation. Eur J Cancer. 2009;45(2):268–274
Masubuchi Y, Nakayama J, Sadakata Y. Protective effects of exogenous glutathione and related thiol compounds against drug-induced liver injury. Biol Pharm Bull. 2011;34(3):366–370
Berk M, Malhi GS, Gray LJ, et al. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013;34(3):167–177
Zwingmann C, Bilodeau M. Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver. Hepatology. 2006;43(3):454–463
Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856–864
Bateman DN, Dear JW, Thanacoody HK, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomized controlled trial. Lancet. 2014;383(9918):697–704
Singh S, Hynan LS, Lee WM, Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci. 2013;58(5):1397–1402
Mao YM, Zeng MD, Chen Y, et al. Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study. Chin J Hepatol 2009;17(11):847–851 (article in Chinese)
Li X, Zhou J, Chen S, et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–914
Chu NH, Li L, Zhang X, et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015;19(4):475–480
Zhang QH, Shi GF, Li Q. Effects of diammonium glycyrrhizinate enteric-coated capsule in the treatment of 2396 cases with chronic hepatitis. Chin J Infect Dis 2007;25(3):175–176 (article in Chinese)
Abenavoli L, Capasso R, Milic N, et al. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423–1432
Ni LD, Xie Q, Li HW, et al. Ursodeoxycholic acid in the treatment of drug-injury: an open controlled clinical trial. Chin Hepatol 2009;14(4):278–280 (article in Chinese)
Zhao P, Duan GF, Du L, et al. Systematic evaluation on the efficacy of ademetionine in patients of drug-induced liver injury. Chin J Gastroenterol Hepatol 2011;20(4):341–344 (article in Chinese)
Mato JM, Lu SC. Role of S-adenosyl-l-methionine in liver health and injury. Hepatology. 2007;45(5):1306–1312
Vincenzi B, Santini D, Frezza AM, et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345–349
Jeong R, Lee YS, Sohn C, et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury. Scand J Gastroenterol. 2015;50(4):439–446
Yu YC, Chen CW. Interpretation of ACG clinical guidelines for the diagnosis and treatment of idiosyncratic drug-induced liver injury. Chin Hepatol 2014;19(8):570–574 (article in Chinese)
Zhang L, Yang XH. Phamacovigilance concept should be introduced sufficiently into the process of safety monitoring and evaluation of Chinese traditional medicine. Chin J Integr Tradit Western Med 2009;29(9):863–866 (article in Chinese)
Zhang L, Wong LY, He Y, Wong IC. Pharmacovigilance in China: current situation, successes and challenges. Drug Saf. 2014;37(10):765–770
Graham DJ, Mosholder AD, Gelperin K, et al. Pharmacoepidemiology and risk management. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. West Sussex: Wiley; 2005. 51530.
Olson S, Robinson S, Giffin R; Institute of Medicine. Accelerating the development of biomarkers for drug safety: workshop summary. National Academies Press. Ibid. Watkins PB, Bloom J, Hunt C. Biomarkers of Acute Idiosyncratic Hepatocellular Injury in Clinical Trials, Chap 5. 2009. 4257